Eton Pharmaceuticals, Inc.

NasdaqGM ETON

Eton Pharmaceuticals, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -17.81

Eton Pharmaceuticals, Inc. Interest Coverage Ratio is -17.81 for the Trailing 12 Months (TTM) ending September 30, 2024, a -682.78% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Eton Pharmaceuticals, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 3.06, a 132.01% change year over year.
  • Eton Pharmaceuticals, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -9.55, a 1.41% change year over year.
  • Eton Pharmaceuticals, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -9.68.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
Loading...
SV Wall Street
NasdaqGM: ETON

Eton Pharmaceuticals, Inc.

CEO Mr. Sean E. Brynjelsen
IPO Date Nov. 13, 2018
Location United States
Headquarters 21925 West Field Parkway
Employees 30
Sector Healthcare
Industries
Description

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Similar companies

BDTX

Black Diamond Therapeutics, Inc.

USD 2.46

-2.38%

NVCT

Nuvectis Pharma, Inc.

USD 6.67

-7.87%

CELC

Celcuity Inc.

USD 12.25

-2.70%

ALEC

Alector, Inc.

USD 1.75

-2.23%

NUVB

Nuvation Bio Inc.

USD 2.38

-1.24%

ELDN

Eledon Pharmaceuticals, Inc.

USD 4.70

-1.05%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.40

-4.76%

TARS

Tarsus Pharmaceuticals, Inc.

USD 52.95

-0.69%

GOSS

Gossamer Bio, Inc.

NA

NA

ELVN

Enliven Therapeutics, Inc.

USD 22.00

-2.09%

TVTX

Travere Therapeutics, Inc.

USD 21.75

-0.50%

ALDX

Aldeyra Therapeutics, Inc.

USD 5.93

-1.17%

REPL

Replimune Group, Inc.

USD 13.94

-0.85%

INBX

Inhibrx Biosciences, Inc.

USD 12.60

-2.70%

StockViz Staff

February 10, 2025

Any question? Send us an email